Abstract
BackgroundIn the Europe, rituximab (RTX), an anti-CD20 monoclonal antibody, is reserved for patients with rheumatoid arthritis (RA) who have failed initial anti-TNF therapy. There is a concern over whether B-cell...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have